Literature DB >> 8002095

Combination effect of meropenem with aminoglycosides and teicoplanin on Pseudomonas and enterococci.

A Kropec1, S Lemmen, M Wursthorn, F D Daschner.   

Abstract

The in vitro activity of meropenem, a new carbapenem, and the combination effect with netilmicin, tobramycin, gentamicin, and teicoplanin against Pseudomonas spp. and enterococci was studied. Meropenem showed very good in vitro activity against Pseudomonas aeruginosa (MIC90 2 mg/l) and good to moderate activity against Pseudomonas putida (MIC90 4 mg/l) and Enterococcus faecalis (MIC90 8 mg/l). Aminoglycosides were highly active against P. putida (MIC90 0.5 mg/l), but showed only moderate activity against P. aeruginosa. The synergistic effect of meropenem was shown in combination with teicoplanin against E. faecalis (40%). No Pseudomonas strains were inhibited by the synergistic effect of meropenem with aminoglycosides. No antagonism occurred with any of the combinations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8002095     DOI: 10.1007/BF01739926

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  Enterococcal infections: an increasing problem in hospitalized patients.

Authors:  M S Terpenning; M J Zervos; D R Schaberg; C A Kauffman
Journal:  Infect Control Hosp Epidemiol       Date:  1988-10       Impact factor: 3.254

2.  Single-concentration broth microdilution test for detection of high-level aminoglycoside resistance in enterococci.

Authors:  M J Zervos; J E Patterson; S Edberg; C Pierson; C A Kauffman; T S Mikesell; D R Schaberg
Journal:  J Clin Microbiol       Date:  1987-12       Impact factor: 5.948

Review 3.  Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.

Authors:  C C Sanders; W E Sanders
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

4.  Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.

Authors:  C Chanal; D Sirot; M Chanal; M Cluzel; J Sirot; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

5.  In-vitro studies of meropenem.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

6.  Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  J A García-Rodríguez; J E García Sánchez; M I García García; E García Sánchez; J L Muñoz Bellido
Journal:  Diagn Microbiol Infect Dis       Date:  1991 May-Jun       Impact factor: 2.803

Review 7.  The carbapenems: new broad spectrum beta-lactam antibiotics.

Authors:  R C Moellering; G M Eliopoulos; D E Sentochnik
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

8.  Nosocomial urinary tract infections due to enterococcus. Ten years' experience at a university hospital.

Authors:  A J Morrison; R P Wenzel
Journal:  Arch Intern Med       Date:  1986-08

9.  Combination effect of azthreonam with four aminoglycosides on nosocomial gram-positive cocci and non-fermenting gram-negative bacteria.

Authors:  H M Just; E Phillips; M Bassler; F D Daschner
Journal:  Eur J Clin Microbiol       Date:  1982-12       Impact factor: 3.267

  9 in total
  3 in total

Review 1.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Evaluation of Aminoglycoside and Carbapenem Resistance in a Collection of Drug-Resistant Pseudomonas aeruginosa Clinical Isolates.

Authors:  Selina Y L Holbrook; Sylvie Garneau-Tsodikova
Journal:  Microb Drug Resist       Date:  2017-12-20       Impact factor: 3.431

Review 3.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.